How Centralized IBC Review Can Benefit Gene Therapy Research
Advarra
AUGUST 8, 2023
As of June 2023, 416 Phase III studies are listed, representing a growing pipeline of gene therapy products preparing to undergo consideration for FDA approval. Risks and Regulatory Requirements Most clinical researchers are familiar with the regulatory requirements pertaining to the FDA phases of review as well as with IRB review.
Let's personalize your content